Medical Technology Regulatory Modernization Market : Global Industry Analysis and Opportunity Assessment, 2036

How big is Medical Technology Regulatory Modernization Market in 2026?

USD 1248.2 million in 2026 and USD 2770.5 million by 2036 at an 8.3% CAGR.

Demand for medical technology regulatory modernization is expected to expand at 8.3% CAGR from 2026 to 2036, increasing valuation from USD 1248.2 million in 2026 to USD 2770.5 million by 2036. Digital submission mandates are increasing demand for regulatory information management platforms that maintain one approved record across changing authority formats. In September 2025, the FDA stated that De Novo submissions would require eSTAR from October 1. The rule covers original requests and later supplements or amendments, which makes consistent product data essential throughout the complete review cycle. Modern platforms reduce repeated document assembly and reveal incomplete fields prior to formal submission, which lowers avoidable rework across active programs. Spending becomes easier to justify if the system lowers avoidable rework and gives each regulatory task a named owner.

Regulatory teams in the United States and Europe rely on the same product history but follow different authority routes. American programs emphasize eSTAR submission structure and QMSR alignment across FDA device review and inspection processes. European programs coordinate mandatory EUDAMED modules with national implementation steps and separate authority responsibilities across member states. A shared platform can reduce handoff errors across internal departments and regulatory affairs outsourcing partners supporting several jurisdictions. Cloud deployment also helps dispersed teams review the same current record without maintaining separate regional copies. Each manufacturer must test migration quality and access controls across representative records prior to retiring established archives or regional systems. The strongest purchasing case combines fewer manual reconciliations with clear responsibility for every submission and continuing authority commitment.

Summary of the Medical Technology Regulatory Modernization Market

Market Signal	Commercial Impact
Demand and Growth Drivers	Regulatory teams create value if one approved product record supports submissions and continuing compliance duties across every active market. The market is projected to rise through 2036 as electronic submission mandates increase demand for structured regulatory data and controlled workflows. Medical-device manufacturers invest in platforms that reduce repeated entry across approvals and post-market actions throughout each active product lifecycle. Linked quality and regulatory records help teams assess submission impacts without rebuilding the same evidence for each authority task. Implementation becomes easier to defend if fewer manual reconciliations shorten avoidable delays across active product portfolios.
Product and Segment View	The product structure combines controlled regulatory data with submission and quality workflows across the complete device lifecycle. Regulatory Information Management Systems are projected to hold 36.4% share in 2026 due to their central product-record role. Medical Device Approval Management is forecast to represent 38.7% share in 2026 through its direct connection with authorization work. Medical Device Manufacturers are estimated to account for 39.8% share in 2026 owing to continuing lifecycle responsibility. Cloud-based Solutions are expected to capture 47.0% share in 2026 as distributed teams seek faster access and managed updates.
Geography and Growth Outlook	Country growth reflects digital authority processes and local validation duties alongside domestic language requirements and implementation support. The UK is projected to record 10.0% CAGR through 2036 as stronger post-market duties expand structured reporting needs. The USA is forecast to post 9.0% CAGR during the forecast period amid electronic submission and quality-system alignment. Japan and Germany maintain distinct portal requirements that increase demand for configurable workflows and local implementation support. South Korean adoption depends on digital-product rules and practical integration across domestic approval and reporting procedures.
Competitive Landscape	Competition spans dedicated regulatory platforms and broader compliance systems that connect quality or submission records with authority-facing workflows. Veeva Systems and ArisGlobal provide regulatory lifecycle platforms covering registrations and submission activities across multiple product classes. Rimsys focuses on medical-device regulatory operations while MasterControl connects regulatory records with established quality-management processes. IQVIA and Ennov combine regulatory information management with connected quality and submission capabilities across regulated product portfolios. Freyr Solutions and Generis support regulatory publishing and integrated compliance workflows designed for medical-device organizations across several jurisdictions.
Analyst Perspective	The commercial test examines whether a platform converts changing authority requirements into controlled work across each product record. Implementation need to begin with a defined submission or registration workflow instead of immediate replacement across every compliance system. Data migration deserves separate validation because incomplete product history can weaken decisions within an otherwise capable platform. Subscription pricing should clarify validation support and configuration ownership so regulatory teams can compare usable capacity across competing offers. - Anurag Sharma, Principal Analyst at Future Market Insights

Source: FMI's proprietary forecasting model and primary research

How is the medical technology regulatory modernization market segmented?

The medical technology regulatory modernization industry is segmented by technology and application with end-user and deployment-model analysis across regions.

Technology separates systems that manage regulatory data from tools that automate submission work or analyze compliance risks. Application categories follow operating tasks across device approval and evidence generation with post-market surveillance and quality compliance under separate workflows. End-user analysis distinguishes manufacturers and biotechnology companies from contract research organizations and regulatory consulting firms with different legal responsibilities. Deployment analysis compares cloud and on-premise models with hybrid systems according to control and maintenance requirements. Regional coverage reflects authority portals and language requirements alongside domestic service capacity and product-specific regulatory routes in each assessed country. The framework keeps software capability separate from the organization using it and the work performed through it.

What supports demand for Regulatory Information Management Systems within the Technology category?

Regulatory teams need one controlled product record linking registrations and submissions with labels and continuing authority commitments. The record must remain accurate as product changes create new filings or updates across several countries. In November 2025 the European Commission confirmed that four EUDAMED modules would become mandatory on May 28 2026. The transition gives manufacturers a direct reason to map device data and ownership prior to mandatory reporting. Life sciences analytics can identify missing records, but the platform must preserve each approved source and accountable owner throughout later regulatory work.

• Regulatory information management systems are set to lead the technology category with 36.4% share in 2026 due to their role as the controlled source for product records. The same governed record supports registrations and submissions with authority correspondence across several jurisdictions, reducing reconciliation during renewals and product changes.
• Global regulatory departments favor RIM platforms that assign every update to a named owner and preserve the approved source record. Most implementations begin with registrations or submission planning prior to adding quality and post-market workflows. A staged rollout limits migration risk and produces clear evidence for broader deployment across additional product portfolios.

How does Medical Device Approval Management shape demand within the Application category?

Approval teams assemble technical evidence and administrative forms under authority formats that check completeness in different ways. Reusable content matters most for manufacturers managing several device families through multiple submission routes and authority formats. Manual assembly increases review effort and makes ownership harder to trace across dossier sections during authority questions or revisions. The operating problem extends beyond document storage and includes controlled handoffs from evidence preparation through publishing and authority response.

• By application, medical device approval management is estimated to hold 38.7% share in 2026 owing to its direct control over authorization work. In June 2026 the FDA confirmed that eSTAR remained mandatory for 510(k) and De Novo submissions. Structured workflows separate evidence preparation from publishing and response ownership throughout the complete review process.
• Regulatory departments adopt approval platforms to connect engineering evidence with clinical data management outputs across each submission section. Strong adoption depends on fewer incomplete packages and clearer responsibility for authority questions across active device programs. Configuration loses value if it adds review steps without reducing rework or delayed authority responses.

Why are Medical Device Manufacturers central to the End User category?

Medical device manufacturers retain legal responsibility for authorization and product changes across every commercial product lifecycle. Their post-market duties also continue through incident review and continuing authority commitments for each active product. Connected records help regulatory staff decide whether a design change requires new filings in affected countries. Fragmented systems separate quality investigations from authorization terms that govern continued product access across affected countries and device classes. Separate systems increase review time and create uncertainty during inspections or reportable events across active portfolios.

• Medical device manufacturers are expected to represent 39.8% of the end-user category in 2026, reflecting their legal responsibility for active product lifecycles. Internal regulatory teams assess design changes and maintain authorizations across every country served by the company. Platform spending supports recurring compliance work instead of a temporary documentation project tied to one submission route.
• Medical-device regulatory teams use modernization platforms to connect design changes with country-specific commitments across active product portfolios. In June 2025 the MHRA strengthened post-market surveillance duties through active monitoring and faster incident responses. Preclinical testing services provide evidence inputs, yet manufacturers retain responsibility for final regulatory decisions and required authority actions.

How are Cloud-based Solutions positioned within the Deployment Model category?

Distributed regulatory teams need secure access to current records without maintaining separate installations in every office. In April 2025 Japan's health ministry issued updated rules for online applications through the Gateway and medical-device web platform. The filing route supports healthcare cloud infrastructure that gives remote teams one controlled workspace for preparation and authority submission. Data residency and validation requirements can extend implementation schedules for manufacturers with several historical repositories.

• Cloud-based solutions are projected to hold 47.0% share within the deployment model category in 2026, underpinned by faster access for distributed regulatory teams. Central configuration gives regional offices one governed workflow and reduces duplicated infrastructure administration across operating locations. Managed updates help smaller departments maintain current software without funding a separate platform engineering function internally.
• Mid-sized manufacturers favor cloud subscriptions that spread implementation costs across predictable operating periods and reduce server administration. Adoption depends on validated access controls and dependable migration support from the software provider throughout implementation and routine regulatory operations. Clear hosting options and service responsibilities give regulatory departments a practical basis for comparing competing platforms.

What are the drivers, restraints, and opportunities in the medical technology regulatory modernization market?

Electronic submission mandates and connected quality records are increasing demand for governed regulatory platforms across medical-device portfolios. Legacy data and country-specific reporting routes can slow adoption through extensive migration work and formal validation requirements.

• Driver: Electronic submission mandates increase demand for controlled regulatory data and repeatable approval workflows across complex medical-device portfolios.
• Restraint: Legacy records and country-specific formats increase migration effort and raise validation risk across established regulatory operations.
• Opportunity: Connected platforms can link approval evidence with quality and post-market actions through one governed product history.

Quality-system alignment is expected to drive demand for platforms that connect regulatory records with documented manufacturing controls. Device manufacturers need one owner for quality changes and submission impacts across linked medical-device portfolios. In February 2026 the FDA made QMSR effective and incorporated ISO 13485:2016 into the device quality framework. The change requires consistent quality information across inspection and submission activities within each affected manufacturing and regulatory process. Platform investment becomes easier to defend if regulatory and quality teams can work from the same controlled product record.

Country-specific reporting formats create a material restraint for manufacturers maintaining parallel records across several authority systems. Migration teams must preserve complete historical cases and configure every national reporting route inside the replacement platform. In May 2025 the MHRA published updated MORE forms and implementation schemas for incident and corrective-action reporting. The revised schemas require local form maintenance across pharmacovigilance services and medical-device vigilance operations managed through separate reporting routes. Implementation costs rise if each reporting route needs separate validation and dependable technical support throughout routine use and future updates.

Digital-product regulation creates a practical opening for platforms that coordinate approvals and lifecycle evidence across software-driven medical technologies. South Korea's MFDS issued an implementation guide in January 2025 following commencement of the Digital Medical Products Act. The guide gives regulatory teams defined approval responsibilities and evidence fields for eClinical software workflows. Providers can serve this need through Korean-language templates and configurable review routes aligned with national classification and submission procedures. Manufacturers retain legal responsibility for every classification and submission decision under the national regulatory framework.

Which country CAGRs are profiled in the medical technology regulatory modernization market?

Country	CAGR
USA	9.0%
UK	10.0%
Germany	8.5%
Japan	8.8%
South Korea	7.5%

How do country-level CAGRs compare in the medical technology regulatory modernization market?

The country forecasts occupy a compressed 2.5-point range across countries modernizing medical-device regulatory workflows. The UK and USA form the upper band with one percentage point separating their approved growth rates. Japan remains close to this group, while Germany sits between Japan and South Korea within the measured range. South Korea sets the lower boundary, yet its forecast does not create a separate low-growth tier. Different authority portals and validation duties mean similar forecasts can produce materially different market-entry conditions.

• The UK and USA remain clustered as both markets digitize authority workflows under demanding evidence requirements. Their similar rates conceal distinct purchasing routes shaped by national oversight and enterprise validation practices within regulated organizations.
• Japan stays near the upper cluster despite language requirements and certificate costs affecting foreign implementation teams. Careful submission preparation and experienced domestic support therefore carry greater commercial importance for multinational manufacturers.
• Germany occupies the middle position as manufacturers prepare for EUDAMED and national device information system changes. Parallel data mapping creates implementation work and raises demand for local configuration support across active product records.
• South Korea defines the lower boundary within a comparison that remains compressed across all five countries. Its digital-product framework creates targeted demand for domestic configuration and specialist training across software-driven devices.
• The forecasts form one compressed band instead of separate high-growth and low-growth groups across the profiled countries. Commercial outcomes depend more on authority integration and service capacity than small differences between approved rates.

Market entry plans should account for authority portals and domestic language support alongside local capacity to validate configured workflows. The full report provides country-level CAGR analysis across North America, Latin America, Europe, East Asia, South Asia, Oceania and the Middle East and Africa.

Country-wise Analysis

• United States device manufacturers use electronic FDA submission routes within a quality framework aligned more closely with ISO 13485. Medical technology regulatory modernization platform sales in the USA are forecast to expand at 9.0% CAGR by 2036, facilitated by mandatory electronic templates and structured quality records. Structured eSTAR templates give software teams a stable configuration target across active 510(k) and De Novo submission programs. In October 2025 the FDA issued draft guidance on quality-management information for certain premarket submission reviews. The guidance creates a direct need to connect quality evidence with submission packages under controlled ownership. Long approval histories and complex migrations can extend purchasing cycles for manufacturers maintaining large portfolios of active products.
• Great Britain combines centralized MHRA oversight with stronger post-market duties and separate routes for continued device access. In July 2025 the MHRA published its response concerning international reliance and proposed UKCA marking routes. Demand for medical technology regulatory modernization platforms in the UK is predicted to advance at 10.0% CAGR through 2036, reinforced by changing market-access and reporting requirements. Remote implementation and cloud subscriptions can support smaller regulatory departments managing several product portfolios across different authority routes. Proposed pathways may simplify selected entry work, yet distinct Great Britain requirements remain part of each configured submission route. Legislative timing creates a material friction that can change configuration schedules and delay commercial planning for implementation teams.
• German manufacturers manage national device procedures and prepare for EUDAMED through updated clinical-investigation workflows across parallel authority systems. Germany's medical technology regulatory modernization market outlook is anticipated to advance at 8.5% CAGR over the assessment period, attributable to parallel European and national reporting requirements. In June 2025 BfArM announced a renewed DMIDS clinical-investigations module for July 1 with improved usability and a new radiation-application route. The update creates direct demand for local-language workflow mapping and validated data migration across affected clinical-investigation records. Experienced domestic consultants provide implementation support across active product records that require national and European authority mapping. Planned service interruptions remain a material friction during system changes involving live regulatory data and active submission programs.
• Japanese regulatory operations use PMDA review routes that require bilingual document preparation and local process knowledge across medical-device submissions. Japan's medical technology regulatory modernization sector is estimated to post 8.8% CAGR over the forecast period, shaped by digital submission routes and structured review information. Bilingual review summaries help global manufacturers compare evidence expectations across selected device categories and documented approval decisions. In March 2025 PMDA announced that Japanese and English review summaries would cover selected medical devices from fiscal 2025. Domestic implementation partners support training and authority communication through procedures that foreign regulatory teams may not manage internally. Limited English coverage creates additional review work for device categories without translated summaries or familiar domestic precedents.
• South Korea operates a specialized digital-medical-product framework alongside established national device approval and reporting procedures. In April 2025 the MFDS issued regulations covering approval and certification with reporting and evaluation requirements for digital medical products. The medical technology regulatory modernization market in South Korea is projected to grow at 7.5% CAGR through 2036, supported by digital-product rules and cloud-ready infrastructure. The regulations provide direct configuration targets for approval and evidence workflows across each regulated digital-product submission route. Domestic specialists support Korean-language implementation and classification decisions across software-driven medical products with different evidence requirements. Product classification increases dependence on specialist services during platform validation and later maintenance of national submission workflows.

Who are the notable companies in the medical technology regulatory modernization market?

Veeva Systems, IQVIA, ArisGlobal, Rimsys, MasterControl, Freyr Solutions, Ennov, and Generis are the notable companies shaping this market.

The competitive field includes dedicated RIM providers and broader compliance platforms that manage regulatory content across product lifecycles. IQVIA describes SmartSolve as one environment for quality and regulatory work across life-sciences product lifecycles. Dedicated RIM providers compete through registration control and submission publishing with authority correspondence across multiple regulated product classes. Broader platforms compete through links with quality and clinical trials workflows that support regulated decisions. Selection depends on verified medical-device coverage and implementation support rather than general company size or unrelated software breadth. Regulatory departments should test migration quality and supported authority formats prior to comparing wider portfolio breadth.

• Veeva Systems and ArisGlobal provide lifecycle platforms covering registrations and submissions with authority correspondence across regulated product portfolios. Rimsys focuses on medical-device regulatory operations and governed product data across global registrations and continuing lifecycle obligations. Their differentiation depends on device-specific configuration and dependable migration support for active authorization records managed globally.
• IQVIA and MasterControl connect regulatory work with quality processes affecting approvals and continuing post-market responsibilities across medical-device portfolios. Ennov combines regulatory information management with submission publishing and quality capabilities designed for regulated medical-device portfolios. The combined platforms suit organizations that need controlled data and connected compliance workflows across several product and country records.
• Freyr Solutions combines submission publishing tools with regulatory services covering several jurisdictions and authority formats. Generis supports applications and registrations with medical-device submissions and health-authority correspondence through the CARA platform. Its quality workflows also cover events and controlled documents across medical-device compliance processes and inspections. Evaluation should focus on exact device coverage and implementation support across active product records before selection.

Competitive Benchmarking: Medical Technology Regulatory Modernization Market

Company	Regulatory Data Management	Submission Workflow	Quality and Post-market	Geographic Reach
Veeva Systems	High	High	High	Global
IQVIA	High	High	High	Global
ArisGlobal	High	High	High	Global
Rimsys	High	High	Medium	Global
MasterControl	Medium	Medium	High	Multi-region
Freyr Solutions	High	High	Medium	Global
Ennov	High	High	High	Global
Generis	High	High	High	Global

Regulatory Data Management is High for a dedicated lifecycle RIM platform and Medium for direct regulated-data support across connected workflows. Low applies to a verified narrow record function that lacks broader lifecycle coverage and never represents missing evidence. Submission Workflow is High for planning plus publishing or authority exchange across an end-to-end regulated submission process. Medium covers submission-ready outputs that provide useful document support but limited control across the complete regulatory lifecycle. Low applies to a documented handoff that lacks planning and publishing control across the complete submission workflow. Quality and Post-market is High for dedicated quality or vigilance capability covering governed investigations and required reporting. Medium covers a direct connection to those processes without managing the complete quality or post-market workflow. Low applies to a verified supporting function that does not manage the complete quality or post-market workflow.

Key Developments in the Medical Technology Regulatory Modernization Market

• In September 2025, Veeva Systems: More than 450 organizations had adopted Veeva RIM on the company's unified regulatory platform. The announcement also described partnerships connecting Veeva RIM with multi-authority collaboration environments across regulated submission processes.
• In March 2025, ArisGlobal: LifeSphere Unify launched with NavaX Insights and Advanced Compliance Docs across the regulated platform portfolio. The platform connects safety and medical affairs data with regulatory and quality information across one environment. The release broadens access to connected information without replacing the governed records supporting formal regulatory work across regulated life-sciences operations.
• In April 2025, Rimsys: The platform added EUDAMED machine-to-machine bulk UDI transmission and Rimsys Connect for enterprise data synchronization. The release gives medtech teams a direct route for bulk device-data submission and near-real-time reporting access across medical-device portfolios.
• In March 2025, Generis formed a partnership with Regenold to connect medical-device regulatory expertise with the CARA platform. The partnership covers regulatory information and quality management for medical-device organizations that need software with specialist implementation support.

Key Players in the Medical Technology Regulatory Modernization Market

Regulatory Information Platform Providers

• Veeva Systems
• ArisGlobal
• Rimsys

Quality and Regulatory Platform Providers

• IQVIA
• MasterControl
• Ennov

Regulatory Content and Submission Providers

• Freyr Solutions
• Generis

Medical Technology Regulatory Modernization Market - Report Scope

Coverage field	Report scope
Market breakdown	Technology, application, end user, deployment model, and region.
Market Definition	Software platforms and related services used to manage medical-technology regulatory information, submissions, approval workflows, compliance evidence, and post-market regulatory responsibilities.
Regions Covered	North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia and Pacific, and Middle East and Africa.
Countries Covered	USA, UK, Germany, Japan, and South Korea.
Key Companies Profiled	Veeva Systems, IQVIA, ArisGlobal, Rimsys, MasterControl, Freyr Solutions, Ennov, and Generis.
Forecast Period	2026 to 2036.
Approach	Hybrid bottom-up and top-down market sizing supported by primary interviews and authoritative desk research.

Medical Technology Regulatory Modernization Market - Research Methodology

Method	Approach
Primary Research	FMI analysts gathered input from manufacturers, service providers, technology developers, distributors, end users, procurement teams, and subject-matter experts. Interviews examined purchasing decisions, product or service evaluation, adoption barriers, approval requirements, pricing considerations, and expectations for technical or commercial support. Respondents were also asked what evidence is required before a trial, pilot, or initial order develops into regular purchasing.
Desk Research	Desk research covered government statistics, regulatory publications, trade data, industry associations, technical literature, standards, company filings, product information, and official corporate announcements. Sources were reviewed for relevance, publication date, geographic coverage, and consistency with the defined market scope. Claims relating to performance, applications, approvals, capacity, investment, and commercial activity were retained only when supported by credible public evidence.
Market Sizing and Forecasting	The market model combined the baseline value with historical performance, segment structure, pricing and volume indicators, adoption levels, company participation, and country-level demand conditions. Forecast assumptions considered economic activity, investment trends, regulatory developments, technology adoption, purchasing cycles, supply availability, and barriers to wider market use. Segment and regional estimates were reconciled before the final market total was calculated.
Data Validation	Estimates were checked against multiple independent indicators, including public data, company activity, trade patterns, industry developments, and findings from primary interviews. Validation also tested whether products, services, applications, and company revenues fell within the defined market boundaries. Adjacent categories, unsupported claims, overlapping revenues, and activities without direct market relevance were excluded to reduce double counting and maintain consistency across segments and countries.

Medical Technology Regulatory Modernization Market by Segments

Medical Technology Regulatory Modernization Market segmented by Technology:

• Regulatory Information Management Systems
• Artificial Intelligence-based Compliance Solutions
• Digital Submission Platforms
• Regulatory Analytics Platforms

Medical Technology Regulatory Modernization Market segmented by Application:

• Medical Device Approval Management
• Clinical Evaluation and Evidence Generation
• Post-market Surveillance
• Quality and Compliance Management

Medical Technology Regulatory Modernization Market segmented by End User:

• Medical Device Manufacturers
• Biotechnology Companies
• Contract Research Organizations
• Regulatory Consulting Firms

Medical Technology Regulatory Modernization Market segmented by Deployment Model:

• Cloud-based Solutions
• On-premise Solutions
• Hybrid Platforms

Medical Technology Regulatory Modernization Market by Region:

• North America
  • United States
  • Canada
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Chile
• Western Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Benelux
  • Nordics
• Eastern Europe
  • Poland
  • Czech Republic
  • Romania
  • Hungary
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia and New Zealand
• Middle East and Africa
  • GCC Countries
  • South Africa
  • Türkiye
  • Israel

Research Sources and Bibliography

• USA Food and Drug Administration. (2025, September 30).
• European Commission. (2025, November 27).
• USA Food and Drug Administration. (2026, June 1).
• Medicines and Healthcare products Regulatory Agency. (2025, June 16).
• Ministry of Health, Labour and Welfare. (2025, April 1).
• USA Food and Drug Administration. (2026, February 2).
• Medicines and Healthcare products Regulatory Agency. (2025, May 16).
• Ministry of Food and Drug Safety. (2025, January 24).
• USA Food and Drug Administration. (2025, October).
• Medicines and Healthcare products Regulatory Agency. (2025, July 22).
• Federal Institute for Drugs and Medical Devices. (2025, June 24)
• Pharmaceuticals and Medical Devices Agency. (2025, March 24).
• Ministry of Food and Drug Safety. (2025, April 15).
• IQVIA. (n.d.).
• ArisGlobal. (n.d.).
• Generis. (n.d.).
• MasterControl. (n.d.).
• Freyr Solutions. (n.d.).
• Freyr Solutions. (n.d.).
• Veeva Systems. (2025, September 2).
• ArisGlobal. (2025, March 19).
• Rimsys. (2025, April 29).
• Generis. (2025, March 31).
• Rimsys. (n.d.).
• Freyr Solutions. (n.d.).

This bibliography is provided for reader reference and is not exhaustive. The full report contains the complete reference list and detailed citations

This Report Answers

• How large is the medical technology regulatory modernization market in 2026 and 2036?
• Which regulatory changes support investment in structured submission and compliance platforms?
• Why do Regulatory Information Management Systems hold the main Technology share in 2026?
• How does Medical Device Approval Management influence authorization workflows and commercial entry?
• Why do Medical Device Manufacturers account for the main End User share in 2026?
• How do country growth rates differ across the USA, UK, Germany, Japan, and South Korea?
• Which companies provide regulatory platforms or connected quality and safety workflows?
• What limits platform adoption across legacy records and local authority formats?
• How can cloud deployment support distributed regulatory teams without weakening validation controls?